Gilead Sciences, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Daniel O'Day
- Full Time Employees
- 17,000
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 333 Lakeside Drive Foster City CA United States of America 94404
- IPO Date
- Jan 22, 1992
- CIK
- 0000882095
- Website
- gilead.com
- Similar Companies
- Business
- Gilead Sciences, Inc. (Nasdaq: GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need, with primary focus areas including HIV/AIDS, viral hepatitis, oncology, inflammation and serious respiratory diseases. The company markets a portfolio of marketed products such as Biktarvy, Descovy, Truvada and Veklury for virology; Epclusa, Vosevi and Vemlidy for liver diseases; Trodelvy, Tecartus and Yescarta for oncology; and investigational assets across its therapeutic areas, including complete regimen single-tablet treatments for HIV, nucleotide reverse transcriptase inhibitors and NS5A/NS5B inhibitors for hepatitis C. Founded in 1987 and headquartered in Foster City, California, Gilead operates globally with facilities across North America, Europe (including international headquarters in Stockley Park, UK), Asia-Pacific (such as Japan, China and Australia) and approximately 17,000 employees worldwide. Recent strategic developments include a $32 billion U.S. investment commitment by 2030 to expand manufacturing and R&D capabilities, highlighted by the September 2025 groundbreaking of a new Pharmaceutical Development and Manufacturing Technical Development Center in Foster City projected to create thousands of jobs; an up-to-$400 million acquisition in November 2025 of Sprint Bioscience's preclinical TREX1 oncology immunotherapy program; a $350 million buyout in August 2025 of Interius BioTherapeutics by subsidiary Kite Pharma to advance in vivo CAR-T cell therapies for cancer; a January 2025 strategic partnership with LEO Pharma acquiring rights to preclinical oral STAT6 inhibitors and targeted protein degraders for inflammatory diseases; and an expanded agreement with Cognizant in early 2025 to enhance productivity through advanced technologies.
Company News
Baird Financial Group Inc. Grows Holdings in Gilead Sciences, Inc. $GILD
Analyzing Gilead Sciences (NASDAQ:GILD) & Grifols (NASDAQ:GRFS)
Gilead Sciences, Inc. (GILD) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Gilead Sciences Sees Sunlenca Launch Fueling Long-Term HIV Growth
Gilead Sciences, Inc. (GILD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Gilead Sciences Eyes HIV, Oncology Catalysts as Pipeline Enters Execution Mode
Gilead Sciences (GILD) Suffers a Larger Drop Than the General Market: Key Insights
Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines
Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines
California State Teachers Retirement System Has $30.47 Billion Stake in Gilead Sciences, Inc. $GILD
Compass Financial Management LLC Invests $671,000 in Gilead Sciences, Inc. $GILD
Gilead Sciences Just Won Its Third FDA Approval in Less Than 4 Months. Is the Stock Still Underrating This Turnaround Play?
Gilead Keeps Writing Bigger Checks—But Can the Drugs Keep Paying for Them?
Why Is Gilead (GILD) Up 13.6% Since Last Earnings Report?
Can Bixlenvo Unlock New Growth for Gilead's HIV Business?
Gilead (GILD) Upgraded to Strong Buy: What Does It Mean for the Stock?
Wall Street Analysts See Gilead (GILD) as a Buy: Should You Invest?
Archer Investment Corp Takes Position in Gilead Sciences, Inc. $GILD
BNP Paribas Purchases 20,329 Shares of Gilead Sciences, Inc. $GILD
Beacon Pointe Advisors LLC Reduces Holdings in Gilead Sciences, Inc. $GILD